These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

208 related articles for article (PubMed ID: 38757022)

  • 1. 2024 Guidelines of the Polish Society of Laboratory Diagnostics and the Polish Lipid Association on laboratory diagnostics of lipid metabolism disorders.
    Solnica B; Sygitowicz G; Sitkiewicz D; Jóźwiak J; Kasperczyk S; Broncel M; Wolska A; Odrowąż-Sypniewska G; Banach M
    Arch Med Sci; 2024; 20(2):357-374. PubMed ID: 38757022
    [TBL] [Abstract][Full Text] [Related]  

  • 2. 2020 Guidelines of the Polish Society of Laboratory Diagnostics (PSLD) and the Polish Lipid Association (PoLA) on laboratory diagnostics of lipid metabolism disorders.
    Solnica B; Sygitowicz G; Sitkiewicz D; Cybulska B; Jóźwiak J; Odrowąż-Sypniewska G; Banach M
    Arch Med Sci; 2020; 16(2):237-252. PubMed ID: 32190133
    [No Abstract]   [Full Text] [Related]  

  • 3. Lipid measurements in the management of cardiovascular diseases: Practical recommendations a scientific statement from the national lipid association writing group.
    Wilson PWF; Jacobson TA; Martin SS; Jackson EJ; Le NA; Davidson MH; Vesper HW; Frikke-Schmidt R; Ballantyne CM; Remaley AT
    J Clin Lipidol; 2021; 15(5):629-648. PubMed ID: 34802986
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Recommendations of the Experts of the Polish Cardiac Society (PCS) and the Polish Lipid Association (PoLA) on the diagnosis and management of elevated lipoprotein(a) levels.
    Sosnowska B; Stepinska J; Mitkowski P; Bielecka-Dabrowa A; Bobrowska B; Budzianowski J; Burchardt P; Chlebus K; Dobrowolski P; Gasior M; Jankowski P; Kubica J; Mickiewicz A; Mysliwiec M; Osadnik T; Prejbisz A; Rajtar-Salwa R; Wita K; Witkowski A; Gil R; Banach M
    Arch Med Sci; 2024; 20(1):8-27. PubMed ID: 38414479
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Position of the Polish Cardiac Society on therapeutic targets for LDL cholesterol concentrations in secondary prevention of myocardial infarctions.
    Mitkowski P; Witkowski A; Stępińska J; Banach M; Jankowski P; Gąsior M; Wita K; Bartuś S; Burchardt P; Farkowski MM; Gierlotka M; Gil R; Leszek P; Sterliński M; Szymański P; Tajstra M; Tycińska A; Wojakowski W
    Kardiol Pol; 2023; 81(7-8):818-823. PubMed ID: 37489830
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Targeting low HDL-cholesterol to decrease residual cardiovascular risk in the managed care setting.
    Cziraky MJ; Watson KE; Talbert RL
    J Manag Care Pharm; 2008 Oct; 14(8 Suppl):S3-28; quiz S30-1. PubMed ID: 19891279
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Results of retrospective chart review to determine improvement in lipid goal attainment in patients treated by high-volume prescribers of lipid-modifying drugs.
    Stacy TA; Egger A
    J Manag Care Pharm; 2006; 12(9):745-51. PubMed ID: 17249907
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Low-density lipoprotein apheresis: an evidence-based analysis.
    Medical Advisory Secretariat
    Ont Health Technol Assess Ser; 2007; 7(5):1-101. PubMed ID: 23074505
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Apolipoprotein B and non-high-density lipoprotein cholesterol reveal a high atherogenicity in individuals with type 2 diabetes and controlled low-density lipoprotein-cholesterol.
    Fonseca L; Paredes S; Ramos H; Oliveira JC; Palma I
    Lipids Health Dis; 2020 Jun; 19(1):127. PubMed ID: 32505210
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [CME-Laboratory 61: New European Consensus Recommendations on Dyslipidemia].
    Eckardstein AV
    Praxis (Bern 1994); 2020; 109(3):215-220. PubMed ID: 32126909
    [TBL] [Abstract][Full Text] [Related]  

  • 11. AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY GUIDELINES FOR MANAGEMENT OF DYSLIPIDEMIA AND PREVENTION OF CARDIOVASCULAR DISEASE.
    Jellinger PS; Handelsman Y; Rosenblit PD; Bloomgarden ZT; Fonseca VA; Garber AJ; Grunberger G; Guerin CK; Bell DSH; Mechanick JI; Pessah-Pollack R; Wyne K; Smith D; Brinton EA; Fazio S; Davidson M
    Endocr Pract; 2017 Apr; 23(Suppl 2):1-87. PubMed ID: 28437620
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Residual dyslipidemia according to low-density lipoprotein cholesterol, non-high-density lipoprotein cholesterol, and apolipoprotein B among statin-treated US adults: National Health and Nutrition Examination Survey 2009-2010.
    Wong ND; Chuang J; Zhao Y; Rosenblit PD
    J Clin Lipidol; 2015; 9(4):525-32. PubMed ID: 26228670
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prognostic Value of the Modified Atherogenic Index of Plasma during Body Mass Reduction in Polish Obese/Overweight People.
    Zalejska-Fiolka J; Hubková B; Birková A; Veliká B; Puchalska B; Kasperczyk S; Błaszczyk U; Fiolka R; Bożek A; Maksym B; Mareková M; Birkner E
    Int J Environ Res Public Health; 2018 Dec; 16(1):. PubMed ID: 30591697
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Residual Atherosclerotic Cardiovascular Disease Risk: Focus on Non-High-Density Lipoprotein Cholesterol.
    Luo Y; Peng D
    J Cardiovasc Pharmacol Ther; 2023; 28():10742484231189597. PubMed ID: 37641208
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of two oral contraceptives containing ethinyl estradiol and gestodene or norgestimate on different lipid and lipoprotein parameters.
    Wiegratz I; Jung-Hoffmann C; Gross W; Kuhl H
    Contraception; 1998 Aug; 58(2):83-91. PubMed ID: 9773262
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Predictive value of remnant lipoprotein for cardiovascular events in patients with coronary artery disease after achievement of LDL-cholesterol goals.
    Nakamura T; Obata JE; Hirano M; Kitta Y; Fujioka D; Saito Y; Kawabata K; Watanabe K; Watanabe Y; Mishina H; Kugiyama K
    Atherosclerosis; 2011 Sep; 218(1):163-7. PubMed ID: 21605862
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Frequency of Attainment of Low-Density Lipoprotein Cholesterol and Non-High-Density Lipoprotein Cholesterol Goals in Cardiovascular Clinical Practice (from the National Cardiovascular Data Registry PINNACLE Registry).
    Spinler SA; Cziraky MJ; Willey VJ; Tang F; Maddox TM; Thomas T; Dueñas GG; Virani SS;
    Am J Cardiol; 2015 Aug; 116(4):547-53. PubMed ID: 26089010
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The utility of non-HDL in managing dyslipidemia of stage 5 chronic kidney disease.
    Pennell P; Leclercq B; Delahunty MI; Walters BA
    Clin Nephrol; 2006 Nov; 66(5):336-47. PubMed ID: 17140163
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Lipid pattern in middle-aged inhabitants of the Lower Silesian region of Poland. The PURE Poland sub-study.
    Skoczyńska A; Wojakowska A; Turczyn B; Zatońska K; Wołyniec M; Regulska-Ilow B; Ilow R; Szuba A; Zatoński W
    Ann Agric Environ Med; 2013; 20(2):317-24. PubMed ID: 23772584
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 11.